Epcoritamab Shows Promise in Large B-Cell Lymphoma
Epcoritamab elicits durable responses in patients with relapsed or refractory large B-cell lymphoma.
All articles by John Eckman
CARMEN Regimen Shows Promise in MYC-Rearranged Aggressive Lymphoma
The CARMEN regimen appears effective in patients with MYC-rearranged aggressive lymphoma, including those who are HIV-positive.
ASH 2022: Trials Show Promising Results in Follicular Lymphoma
Results from 4 trials presented at ASH 2022 may help inform the treatment of newly diagnosed and relapsed/refractory follicular lymphoma.
Asciminib Shows Early Promise as Frontline Therapy for CML-CP
Early results appear promising for frontline asciminib in patients with chronic phase chronic myeloid leukemia, according to researchers.
Consolidative Stem Cell Transplant May Improve Outcomes in PTCL
Researchers sought to determine whether patients with PTCL who have a complete response after A+CHP would benefit from SCT.
Bendamustine-Rituximab Induction Appears Effective in Mantle Cell Lymphoma
First-line bendamustine plus rituximab followed by ASCT and rituximab maintenance appears effective in mantle cell lymphoma.
Zanubrutinib Appears Superior to Ibrutinib in Patients With Relapsed/Refractory CLL/SLL
Researchers sought to compare zanubrutinib with ibrutinib in patients with CLL/SLL.
Venetoclax Plus Azacitidine Appears Promising in High-Risk MDS, CMML
Researchers sought to determine whether azacitidine plus venetoclax would be effective in patients with high-risk MDS or chronic myelomonocytic leukemia.
Immunotherapy and Targeted Therapies in NSCLC: Phase 3 Data From ESMO 2022
Results from the CodeBreak 200, EMPOWER-Lung 1, IPSOS, and ADAURA trials highlight the efficacy of immunotherapy and targeted therapies in non-small cell lung cancer.
Real-World Analysis Reveals Treatment, Survival Trends in Mantle Cell Lymphoma
Researchers sought to determine the treatment and survival trends for patients with mantle cell lymphoma.
- Loading...
Loading...
Next post in Lymphoma
Loading... 
Loading...